Docket No.: PF-0208-1 DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hillman et al.

Title:

NOVEL HUMAN INTEGRAL MEMBRANE PROTEIN

Serial No.:

09/207,161

Filing Date:

December 7, 1998

Examiner:

Carlson, K.

Group Art Unit:

1653

Assistant Commissioner for Patents Washington, D.C. 20231

CERTIFICATE UNDER 37 C.F.R. §3.73(b), REVOCATION OF POWER OF ATTORNEY AND APPOINTMENT OF NEW ATTORNEYS

Sir:

The undersigned has reviewed all the documents in the chain of title of the aboveidentified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

Incyte Pharmaceuticals, Inc., having a principal place of business located at 3160 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 8540, Frame 0003, hereby revokes all previous powers of attorney and appoints the following patent attorneys/agents:

Narinder S. Banait Adam Warwick Bell Lucy J. Billings Michael C. Cerrone Diana Hamlet-Cox Matthew R. Kaser Peng Ben Wang Amir A. Naini Reg. No. 43,482 Reg. No. 43,490 Reg. No. 36,749 Reg. No. 39,132

Reg. No. 33,302 Reg. No. 44,817 Reg. No. 41,420 Reg. No. P-45,770

Deket No.: PF-0208-1 DIV

Lynn E. MurryReg. No. 42,918Danielle M. PasqualoneReg. No. 43,847Susan K. SatherReg. No. 44,316David G. StreeterReg. No. 43,168Christopher TurnerReg. No. 45,167

Please direct all correspondence to:

Legal Department
Incyte Pharmaceuticals, Inc.
3174 Porter Drive
Palo Alto, California 94304

and direct all telephone calls and facsimile transmissions to: <u>Danielle M. Pasqualone</u>, Incyte Pharmaceuticals, Inc., Phone: (650) <u>845-4892</u>, Fax: (650) 849-8886.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

INCYTE PHARMACEUTICALS, INC.

Date: February 22, 2000 By: Lee Shully

Lee Bendekgey

VP, General Counsel/Corporate Secretary